Key facts
- This page summarizes Patrick Lamy's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
- 8 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 09 Dec 2025, 10:06.
Patrick Lamy - 09 Dec 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)
- Reporting relationship
- Senior VP, Commercial Strategy
- Issuer ticker
- AKRO
- Reported as of
- 09 Dec 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Dec 2025, 10:06:21 UTC
- Prior SEC filing
- 03 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Young, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Patrick Lamy filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 09 Dec 2025.
Change
- Previous filing in this sequence was filed on 03 Jul 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001961273
Primary reporting owner
Lamy Patrick
- Relationship
- Senior VP, Commercial Strategy
- Address
- C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO
- Signature
- /s/ Jonathan Young, Attorney-in-Fact
- Signature date
- 09 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKRO
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -3,059
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 09 Dec 2025
- Ownership
- Direct
- Footnotes
- F1
AKRO
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -26,832
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 09 Dec 2025
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKRO
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -3,421
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 09 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,421
- Exercise price
- $29.23
- Footnotes
- F4
AKRO
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -382
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 09 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 382
- Exercise price
- $19.87
- Footnotes
- F4
AKRO
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -11,096
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 09 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,096
- Exercise price
- $44.37
- Footnotes
- F4
AKRO
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -48,679
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 09 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 48,679
- Exercise price
- $29.23
- Footnotes
- F4
AKRO
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -64,182
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 09 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 64,182
- Exercise price
- $19.87
- Footnotes
- F4
AKRO
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -84,904
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 09 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 84,904
- Exercise price
- $44.37
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Patrick Lamy is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration").
Footnote F2
Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
Footnote F3
Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
Footnote F4
Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
SEC remarks
Senior VP, Commercial Strategy